Corcept Therapeutics (CORT) Appoints Joshua M. Murray to Board of Directors

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Joshua M. Murray has joined the company’s Board of Directors.

Mr. Murray is currently Senior Vice President, Finance, Strategy and Investor Relations at Orca Bio, a privately held biotechnology company developing allogeneic cell therapies in blood, immune, and genetic diseases. Prior to joining Orca, Mr. Murray spent 15 years at Goldman Sachs, most recently as a Managing Director in the Investment Banking Division, where he advised a wide array of biotechnology and life sciences companies. He received an AB in History and Economics from Harvard College.

“I am very pleased to welcome Josh to our board,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “His extensive experience counseling healthcare companies confronting the challenges and opportunities of growth will help us as we bring Korlym® to more patients and advance our pipeline of proprietary, selective cortisol modulators.”

You May Also Be Interested In

• Corcept Therapeutics (CORT) Reports Positive Results From Open-Label Portion of Phase 3 GRACE Trial
• Truist Financial Corp. (TFC) shareholders elect Laurence Stein to board of directors
• Centessa Pharmaceuticals (CNTA) Announces $100 Million Proposed Public Offering of American Depositary Shares